Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo

2008 ◽  
Vol 18 (3) ◽  
pp. 476-486 ◽  
Author(s):  
M. SU ◽  
Y.-J. FENG ◽  
L.-Q. YAO ◽  
M.-J. CHENG ◽  
C.-J. XU ◽  
...  

The aim of this study is to investigate the plasticity of human epithelial ovarian cancer cell SKOV3ip and formation of vasculogenic mimicry (VM) in vivo. SKOV3ip was transfected with lentiviral vector carrying green fluorescence protein (GFP). Female nude mice were implanted intraperitoneally with GFP-labled SKOV3ip. When the transplanted tumor reached a volume of approximately 1 cm3, paraffin-embedded, formaldehyde-fixed tissue was prepared and stained with hematoxylin and eosin (H & E). Tumor tissues were also studied by electron microscopy and fluorescence microscopy. The results of H & E staining, electron microscopy, and fluorescence microscopy indicated SKOV3ip formed patterned networks with erythrocytes in them, in the absence of vascular epithelial cells, which was a sign that SKOV3ip engaged in VM in vivo. Expression of vascular epithelium marker CD31 was investigated by immunohistochemical staining, immunofluorescence assay, semiquantitative reverse transcriptase–polymerase chain reaction (RT-PCR), and flow cytometric analysis (FACS). Factor VIII and vascular endothelial growth factor (VEGF) were also analyzed by FACS. Weak and focal CD31 immunohistochemical staining was found along the channels of tumor cells. Immunofluorescence assay and RT-PCR demonstrated that CD31 was expressed in primary-cultured SKOV3ip. CD31 and Factor VIII, but not VEGF were detected in primary-cultured SKOV3ip by FACS. The present study has shown that human ovarian cancer cell line SKOV3ip may be able to express some specific markers of vascular epithelial cells and has plasticity to form VM in vivo. In the following study, we indicated that hypoxia-inducible factor (HIF)-1α inhibitor, rapamycin, could possibly prevent VM and phenotype transformation of SKOV3ip, reflected by down-regulating expression of CD31 and Factor VIII. HIF-1α protein expression correlated with CD31 and Factor VIII protein expression in SKOV3ip. These results indicated that VM might be associated with HIF-1α.

2012 ◽  
Vol 125 ◽  
pp. S45
Author(s):  
S. Ingersoll ◽  
S. Ahmad ◽  
G. Stoltzfus ◽  
M. Merchant ◽  
A. Ahmed ◽  
...  

Oncogenesis ◽  
2012 ◽  
Vol 1 (9) ◽  
pp. e27-e27 ◽  
Author(s):  
P Wojnarowicz ◽  
K Gambaro ◽  
M de Ladurantaye ◽  
M C J Quinn ◽  
D Provencher ◽  
...  

2020 ◽  
Vol 2 (5) ◽  
Author(s):  
Made VW Yani ◽  
Ida Ayu W Anjani ◽  
I Gede S Narayana ◽  
Desak M Wihandani ◽  
I Gede P Supadmanaba

Ovarian cancer is one of the major health problems in gynecology worldwide. Globocan 2012 data shows that ovarian cancer occurs in 239.000 cases, and is placed fourth as the most malignancy occurred in Indonesia. So far, cisplatin is the most effective therapeutic agent, but the high dosage of administration often caused side effects. A new alternative therapy to overcome the problems by using withaferin-A and nanoparticle PEGylated liposome. WFA has the potential effect to reduce cisplatin resistance but has low bioavailability thus, it needs to be encapsulated. This review’s goal is to depict the potency of withaferin-A, cisplatin, and PEGylated liposome combination as a therapeutic agent to treat ovarian cancer. The combination of Cisplatin-Withaferin PEGylated Liposome is constructed by the modified thin lipid film hydration method then administered orally. This combination suppresses 70-80% of the ovarian cancer cell growth in vivo and inhibits NGFR from binding to TRKA, prevents cell migration as much as 50%. Nano-Cisferin-Liposome, inhibits migration of ovarian cancer cell significantly through ?-catenin signaling through ALDH1 that disturb the spheroid formation, and increase apoptosis event as much 70-80% by increasing ROS production up to 2,5 times. Thus, Nano-Cisferin-Liposome (NCL) has potential as a therapeutic agent for treating ovarian cancer.   Keywords: Cisplatin; Ovarian Cancer; PEGylated Liposome; Withaferin A


2013 ◽  
Vol 8 (2) ◽  
pp. 373-378 ◽  
Author(s):  
SHU LI ◽  
LIHUA QIU ◽  
BUCHU WU ◽  
HAORAN SHEN ◽  
JING ZHU ◽  
...  

2012 ◽  
Vol 29 (2) ◽  
pp. 515-522 ◽  
Author(s):  
HONG LUAN MAO ◽  
YINGXIN PANG ◽  
XIAOLEI ZHANG ◽  
FANG YANG ◽  
JINGFANG ZHENG ◽  
...  

2015 ◽  
Vol 138 (2) ◽  
pp. 372-377 ◽  
Author(s):  
Anirban K. Mitra ◽  
David A. Davis ◽  
Sunil Tomar ◽  
Lynn Roy ◽  
Hilal Gurler ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
Simon J. Hogg ◽  
Kenny Chitcholtan ◽  
Wafaa Hassan ◽  
Peter H. Sykes ◽  
Ashley Garrill

Resveratrol has aroused significant scientific interest as it has been claimed that it exhibits a spectrum of health benefits. These include effects as an anti-inflammatory and an antitumour compound. The purpose of this study was to investigate and compare any potential antigrowth effects of resveratrol and two of its derivatives, acetyl-resveratrol and polydatin, on 3D cell aggregates of the EGFR/Her-2 positive and negative ovarian cancer cell lines SKOV-3 and OVCAR-8, respectively. Results showed that resveratrol and acetyl-resveratrol reduced cell growth in the SKOV-3 and OVCAR-8 in a dose-dependant manner. The growth reduction was mediated by the induction of apoptosis via the cleavage of poly(ADP-ribose) polymerase (PARP-1). At lower concentrations, 5 and 10 µM, resveratrol, acetyl-resveratrol, and polydatin were less effective than higher concentrations, 50 and 100 µM. In SKOV-3 line, at higher concentrations, resveratrol and polydatin significantly reduced the phosphorylation of Her-2 and EGFR and the expression of Erk. Acetyl-resveratrol, on the other hand, did not change the activation of Her-2 and EGFR. Resveratrol, acetyl-resveratrol, and polydatin suppressed the secretion of VEGF in a dose-dependant fashion. In the OVCAR-8 cell line, resveratrol and acetyl-resveratrol at 5 and 10 µM increased the activation of Erk. Above these concentrations they decreased activation. Polydatin did not produce this effect. This study demonstrates that resveratrol and its derivatives may inhibit growth of 3D cell aggregates of ovarian cancer cell lines via different signalling molecules. Resveratrol and its derivatives, therefore, warrant furtherin vivoevaluation to assess their potential clinical utility.


2015 ◽  
Vol 137 ◽  
pp. 204
Author(s):  
J. Hunn ◽  
J. Turbov ◽  
R. Rosales ◽  
V. Syed ◽  
T.P. Conrads ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document